Equol (S-equol) and bone

What 2 graded rows on equol (s-equol) agree on for bone, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Equol (S-equol) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Equol (S-equol) page, with its PubMed record.

Supplement

Equol (S-equol) Choose another

2 rows · 153 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade C, is a randomized trial of 93 people (2011) and found an improvement.

The rows run from 60 to 93 people, published from 2011 to 2023: 2 single studies.

2 improved

Grade CBone resorption and whole-body bone density · Improved
RCT · n 93 · 2011 · Non-equol-producing postmenopausal Japanese women (pilot)
2, 6 or 10 mg/day · 12 months
With 10 mg/day, urinary deoxypyridinoline, a marker of bone breakdown, fell 23.94% vs 2.87% with placebo (P = 0.020), and whole-body bone density did not fall. Sex and thyroid hormones did not differ between groups.
Row on the Equol (S-equol) page · PubMed 21252728 (opens PubMed)
Grade CBone turnover markers and whole-body bone density (with resveratrol) · Improved
RCT · n 60 · 2023 · Healthy postmenopausal women (Italy); equol producer status not tested
10 mg equol plus 25 mg resveratrol once daily · 12 months
Deoxypyridinoline, osteocalcin and bone-specific alkaline phosphatase improved versus placebo (p < 0.0001 for all); TRACP-5b did not change significantly (p = 0.051). Whole-body bone density rose versus placebo (p = 0.022).
Row on the Equol (S-equol) page · PubMed 37569440 (opens PubMed)